Approval of Mellozzan (melatonin)

The pharmaceutical Mellozzan tablets 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg, has been approved for sale in Sweden by the Medical Products Agency.

Mellozzan is a prescription drug used to treat insomnia in children 6 - 17 years of age with ADHD where other sleep support measures are not sufficient. It can also be taken by adults to treat the effects of jet lag for a short time.

Mellozzan contains the hormone melatonin, a synthetic form of the body's own hormone that the brain produces to promote sleep. Medicines containing melatonin are available in Sweden in the form of prolonged-release tablets for the treatment of insomnia in the elderly and tablets for the treatment of jet lag in adults. But for the group of children with ADHD, so far there has only been pharmacy-manufactured licensed medicine, so-called ex-tempora, on the market.

The product is expected to be launched during the current financial quarter.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 16 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.